After working in his father’s pharmaceutical distribution business in
Kolkata, Dilip Shanghvi decided to start manufacturing his own medicines. In 1983, he founded
Sun Pharmaceutical Industries with a small loan from his father, focusing initially on psychiatric drugs. The company began with a single manufacturing facility in Vapi, Gujarat. Sun Pharma steadily expanded its product range and market reach over the next decade. By 1993, profits had grown significantly, allowing Shanghvi to invest in dedicated research and development facilities. Under his leadership, Sun Pharma became known for its strategy of acquiring other companies to fuel growth. The most notable was the $4 billion acquisition of
Ranbaxy Laboratories in 2014, which made Sun Pharma India’s largest pharmaceutical company and among the top global generic drug makers. Despite facing regulatory challenges and a drop in profits between 2014 and 2018, Shanghvi steered the company through recovery. By 2023, Sun Pharma reported profits exceeding ₹8,000 crore, with strong growth in its specialty medicines segment. Shanghvi has also overseen international acquisitions, including US-based Ocular Technologies in 2016 and Concert Pharmaceuticals in 2023, expanding Sun Pharma’s global footprint in specialty drugs. == Community ==